Reviews Ionsys


No reviews yet.

Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006




Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006




Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006




Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006




Ionsys Drug Description

IONSYS™
(fentanyl iontophoretic transdermal system) 40 mcg*/activation
Patient-activated
* Equals to 44.4 mcg fentanyl HCl

IONSYS™ should only be used for the treatment of hospitalized patients. Treatment with IONSYS™ should be discontinued before patients are discharged from the hospital.
Treatment with fentanyl, the active component of IONSYS™, may result in potentially life-threatening respiratory depression and death. To avoid potential overdosing, only the patient should activate IONSYS™ dosing.
Inappropriate use of IONSYS™, leading to ingestion or contact with mucous membranes or unintended exposure to the fentanyl hydrogel could lead to the absorption of a potentially fatal dose of fentanyl. Therefore, the hydrogels should not come into contact with fingers or mouth.
IONSYS™ contains fentanyl, a potent opioid agonist and Schedule II controlled substance with high potential for abuse similar to hydromorphone, methadone, morphine, and oxycodone. Fentanyl can be abused in a manner similar to other opioid agonists, legal or illicit. This should be considered when prescribing or dispensing IONSYS™ in situations where the Health Care Professional is concerned about an increased risk of misuse, abuse, or diversion. After the maximum dosage administration, a significant amount of fentanyl remains in the device.
IONSYS™ should always be kept out of reach of children.
DRUG DESCRIPTION



What are the possible side effects of fentanyl transdermal (Ionsys)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.
Tell your caregivers right away if you have any of these serious side effects:

weak, shallow breathing;
severe weakness, feeling light-headed or fainting;
cold, clammy skin; or
pale skin, easy bruising or bleeding.

Less serious side effects may include:

...
Read All Potential Side Effects for Ionsys »




IONSYS™ (fentanyl iontophoretic transdermal system) is a patient-controlled iontophoretic transdermal system providing on-demand systemic delivery of fentanyl, an opioid agonist, for up to 24 hours or a maximum of 80 doses, whichever comes first.
The chemical name is propanamide, N-phenyl-N-[1-(2-phenylethyl)-4- piperidinyl] monohydrochloride. The structural formula is:
The molecular weight of fentanyl hydrochloride is 372.93, and the empirical formula is C22H28N2O脗路 HCl. The n-octanol:water partition coefficient is 860:1; the pKa is 8.4.
The active ingredient in IONSYS™ is fentanyl. IONSYS™ contains 10.8 mg of fentanyl hydrochloride equivalent to 9.7 mg of fentanyl. IONSYS™ is designed to deliver a 40-mcg dose of fentanyl (equivalent to 44.4 mcg of fentanyl hydrochloride) over a 10-minute period upon each activation of the dose button (see DOSAGE AND ADMINISTRATION).
The inactive ingredients in the IONSYS™ hydrogels consist of cetylpyridinium chloride, USP; citric acid, USP; polacrilin; polyvinyl alcohol; sodium citrate, USP; sodium chloride, USP; sodium hydroxide; and purified water, USP.
System Components and Structure
Each IONSYS™ system is composed of a plastic top housing that contains the battery and electronics, and a red plastic bottom housing containing two hydrogel reservoirs and a polyisobutylene skin adhesive. Only one of the hydrogels (the anode, located under the dosing button) contains fentanyl HCl, along with inactive ingredients. The other hydrogel (the cathode) contains only pharmacologically inactive ingredients. The bottom housing has a red tab that is used only for system removal from the skin and during disposal (see DOSAGE AND ADMINISTRATION, Disposal). A siliconized clear, plastic release liner covers the hydrogels and must be removed and discarded prior to placement on the skin. The system is powered by a 3-volt lithium battery. IONSYS™ (fentanyl iontophoretic transdermal system) Last reviewed on RxList: 7/13/2006





Other reviews about Ionsys on wordpress

Newsweek on Chronic Pain Research & Treatment
  by kerriesmyres
Pain research and treatment are the topics of this week's Newsweek cover story. The article centers on chronic pain caused by physical injuries in war, but it has […]


Monday May 30, 2005
  by pharmaweenie
ChronicleMONDAY From the publishers of THE CHRONICLE OF CANCER THERAPY, THE CHRONICLE OF CARDIOVASCULAR & INTERNAL MEDICINE, THE CHRONICLE OF NEUROLOGY & PSYCHIATY, THE CHRONICLE OF SKIN & ALLERGY, […]


Monday May 29, 2006
  by pharmaweenie
ChronicleMONDAY From the publishers of THE CHRONICLE OF CANCER THERAPY, THE CHRONICLE OF CARDIOVASCULAR & INTERNAL MEDICINE, THE CHRONICLE OF NEUROLOGY & PSYCHIATY, THE CHRONICLE OF […]


Surgery
  by ndeezer
I'm not sure what time they woke me up, must be around 7:00. Lots of nurses and doctors came to tell me that today was the day. One […]


27 days after surgery
  by ndeezer
This morning was the first time that I was allowed to use my shoulder muscles again. Assisted by the physiotherapist, that is. I'm only allowed to lift the […]


Pro Narcotic Promotion
  by angels4drugawarenessvp
Pain Relief Promotions Act Not only are certain drug companies vigorously promoting a narcotic ridden world, but so are some well intentioned patient groups and a number of foolish […]


Cadence Pharmaceuticals Signs Option Agreement to Acquire Incline Therapeutics
  by Biotechtrader
Company Also Closes $30 Million Debt Financing SAN DIEGO, June 21, 2010 /PRNewswire via COMTEX/ -- Cadence Pharmaceuticals, Inc. (CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing […]


Incline Therapeutics acquires analgesia candidate from ALZA
  by silico
Incline Therapeutics has announced that it has entered into an agreement to acquire the rights to IONSYS from ALZA Corporation and completed a $43 million Series A financing. […]



Other reviews about Ionsys on web:

Learn about the prescription medication Ionsys (Fentanyl Iontophoretic Transdermal System), drug uses, dosage, side effects, drug interactions, warnings, reviews and patient ... Ionsys (Fentanyl Iontophoretic Transdermal System) Drug ...


Ionsys (fentanyl transdermal) is used in hospital to treat acute pain after surgery. Includes Ionsys side effects, interactions and indications. Ionsys Information from Drugs.com


Accurate, FDA approved Ionsys information for healthcare professionals and patients - brought to you by Drugs.com. Ionsys Official FDA information, side effects and uses.


|Regulatory Affairs | Airworthiness | Certification | Validation | Qualification | | Quality Management | Project Management | Risk Management | Crisis Management | IONSYS Engineering | Regulatory Affairs | Airworthiness ...


New data released at the World Congress of Anaesthesiologists (WCA) show that IONSYS脙垄脗聞脗垄 (fentanyl iontophoretic transdermal system - ITS) may save hospital staff time compared to ... Study Finds IONSYS脙垄脗聞脗垄, A New Needle-Free System For Management Of ...


Learn about Ionsys (Fentanyl Iontophoretic Transdermal System) - Side Effects, Drug Interactions, Pictures, Patient Information on RxList Ionsys (Fentanyl Iontophoretic Transdermal System) Patient Drug ...


IONSYS脙垄脗聞脗垄, the highly innovative needle-free system for the management of acute post-operative pain, available in Germany, the UK and Ireland IONSYS脙垄脗聞脗垄, the highly innovative needle-free system for the ...


Fentanyl (also known as fentanil, brand names Sublimaze, Actiq, Durogesic, Duragesic, Fentora, Onsolis, Instanyl, and others) is a synthetic strong agonist at the mu and kappa opioid ... Fentanyl - Wikipedia, the free encyclopedia


Ionsys Information, Learn About Ionsys, Ionsys Forums, How to Take Ionsys, Ionsys Side Effects, Ionsys Interactions, Discussion Threads, Medication Warnings, Ionsys Overdose ... Ionsys - The People's Medicine Community


Learn more about Ionsys. Find the Web's best health guides, medical reports, news, videos and tools for Ionsys. Share Ionsys experiences and get advice from experts. Ionsys Overview - References, Advice, News, Videos, Coping & Support





Featured Reviews

Reviews Gabapentin

Neurontin Drug Description Neurontin® (gabapentin) Capsules Neurontin® (gabapentin)Tablets Neurontin® (gabapentin) Oral Solution DRUG DESCRIPTION What are the possible side effects of gabapentin (Gabarone,...
Read More  |  Review This
Reviews Bleomycin Sulfate Injection

Blenoxane Drug Description BLENOXANE® (bleomycin sulfate) for Injection, USP WARNING It is recommended that BLENOXANE be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic...
Read More  |  Review This
Reviews Promethazine HCl and Dextromethorphan Hydrobromide Syrup

Promethazine HCl and Dextromethorphan Hydrobromide Syrup Drug Description Promethazine HCl and Dextromethorphan Hydrobromide (promethazine HCl and dextromethorphan hydrobromide) Syrup DRUG DESCRIPTION What are the possible side effects...
Read More  |  Review This
Reviews Emadine

Emadine Drug Description Emadine® (emedastine difumarate) Ophthalmic Solution 0.05% DRUG DESCRIPTION What are the possible side effects of emedastine ophthalmic (Emadine)? Serious side effects are not expected to occur with...
Read More  |  Review This
Reviews Prevacid NapraPAC

Prevacid NapraPAC Drug Description PREVACID® NapraPAC ® 500 (lansoprazole delayed-release 15 mg capsules and naproxen 500 mg) Tablets kit Cardiovascular Risk NSAIDs may cause an increased risk of serious cardiovascular...
Read More  |  Review This
Recent News
59sec - the BEST lead management system around!
We tested 59sec - THE lead management system and we love it. 59sec helps small and medium companies to answer leads in maximum 59 seconds. Why...
MOVEorPAY - our favorite facebook app
We do love MOVEorPAY motivational facebook app, because it is very cool and useful. It makes you finish stuff that you know are good for you, but from various reasons, you never do...
ReviewsAZ is almost ready to be officially launched
yes, we have just a few loose ends to tie and we are ready to go :) meanwhile, I am putting some reviews on the site, so people will not get an empty site at the launch....